In the Eurofever Registry (45) anti-IL1 treatment with anakinra was shown to be superior to etanercept, and indeed, recently an open-label canakinumab study (49) and placebo-controlled trial (39) confirmed efficacy of anti-IL1 therapies in TRAPS which led to licencing of canakinumab by U.S. Food and Drug Administration and European Medicines Agency. Here, IL1A is linked to TNF receptor 1-associated periodic fever syndrome.